Evidence map›Paper›PMID 42899594›Full record

ReviewBiochemistry2026

In Pursuit of Enduring Inactivation: A Perspective on the Development and Study of Irreversible-Covalent Inhibitors.

Matthias Gehringer, David E Heppner

Abstract readReview
In one paragraph

Review in Biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthias GehringerDepartment of Medicinal Chemistry, Institute for Biomedical Engineering, Faculty of Medicine, Eberhard Karls Universität Tübingen, Tübingen72076, Germany.ORCID 0000-0003-0163-3419
David E HeppnerDepartment of Chemistry, College of Arts and Sciences, The State University of New York at Buffalo, Buffalo, New York14260, United States.ORCID 0000-0002-0722-5160

Funding

Deutsche Forschungsgemeinschaft EXC 2180-390900677Deutsche Krebshilfe 70115201H2020 Marie Sklodowska-Curie Actions 101168624NIGMS NIH HHS 5R35GM155353
6 · The paper itself

Abstract

Molecules that form irreversible covalent bonds with their targets are a mainstay of drug discovery and chemical biology research. Their ability to permanently inactivate an enzyme target provides a mechanism with significant potential to modulate disease phenotypes. This perspective discusses the trajectory of the field of irreversible enzyme inhibitors with an outlook on emerging methods, warhead structures, and sentiments presently directing practices in the discovery and design of the next wave of covalent agents.

Indexed as

Drug DiscoveryEnzyme InhibitorsAnimalsDrug DesignHumansEnzyme Inhibitors

Identifiers

PMID42899594
PMCPMC13689819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.